Nektar And Collaborators Present Late-Breaking Results From Phase 2 Study Of NKTR-255 For The Treatment Of Radiation Induced Lymphopenia In Locally Advanced Non-Small Cell Lung Cancer Patients At SITC Annual Meeting; Demonstrated Statistically Significant Lymphocyte Recovery Compared To Historical Controls At Week 8
– NKTR-255 administered post completion of concurrent chemoradiation and in combination with durvalumab demonstrated statistically significant lymphocyte recovery compared to historical controls at week 8 –
– Pharmacodynamic data show NKTR-255 increased NK cell proliferation and markers of NK cell activation –
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and collaborators at The University of Texas MD Anderson Cancer Center today presented late-breaking results from a Phase 2 study evaluating NKTR-255 for the treatment of radiation induced lymphopenia after concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
